215 related articles for article (PubMed ID: 38593781)
1. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
Huang X; Li Y; Zhang J; Yan L; Zhao H; Ding L; Bhatara S; Yang X; Yoshimura S; Yang W; Karol SE; Inaba H; Mullighan C; Litzow M; Zhu X; Zhang Y; Stock W; Jain N; Jabbour E; Kornblau SM; Konopleva M; Pui CH; Paietta E; Evans W; Yu J; Yang JJ
Cancer Cell; 2024 Apr; 42(4):552-567.e6. PubMed ID: 38593781
[TBL] [Abstract][Full Text] [Related]
2. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia.
Polak R; Bierings MB; van der Leije CS; Sanders MA; Roovers O; Marchante JRM; Boer JM; Cornelissen JJ; Pieters R; den Boer ML; Buitenhuis M
Haematologica; 2019 Apr; 104(4):738-748. PubMed ID: 30381299
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Usami I; Imamura T; Takahashi Y; Suenobu SI; Hasegawa D; Hashii Y; Deguchi T; Hori T; Shimada A; Kato K; Ito E; Moriya-Saito A; Kawasaki H; Hori H; Yumura-Yagi K; Hara J; Sato A; Horibe K;
Int J Hematol; 2019 Apr; 109(4):477-482. PubMed ID: 30689137
[TBL] [Abstract][Full Text] [Related]
5. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
Appel IM; den Boer ML; Meijerink JP; Veerman AJ; Reniers NC; Pieters R
Blood; 2006 Jun; 107(11):4244-9. PubMed ID: 16497975
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Kang SM; Rosales JL; Meier-Stephenson V; Kim S; Lee KY; Narendran A
Oncogene; 2017 Oct; 36(42):5910-5913. PubMed ID: 28650467
[TBL] [Abstract][Full Text] [Related]
9. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.
Shalapour S; Hof J; Kirschner-Schwabe R; Bastian L; Eckert C; Prada J; Henze G; von Stackelberg A; Seeger K
Haematologica; 2011 Nov; 96(11):1627-35. PubMed ID: 21828124
[TBL] [Abstract][Full Text] [Related]
10. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
[TBL] [Abstract][Full Text] [Related]
11. Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase.
Hlozkova K; Pecinova A; Alquezar-Artieda N; Pajuelo-Reguera D; Simcikova M; Hovorkova L; Rejlova K; Zaliova M; Mracek T; Kolenova A; Stary J; Trka J; Starkova J
BMC Cancer; 2020 Jun; 20(1):526. PubMed ID: 32503472
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
[TBL] [Abstract][Full Text] [Related]
13. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Laranjeira AB; de Vasconcellos JF; Sodek L; Spago MC; Fornazim MC; Tone LG; Brandalise SR; Nowill AE; Yunes JA
Leukemia; 2012 May; 26(5):1001-11. PubMed ID: 22005787
[TBL] [Abstract][Full Text] [Related]
14. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy.
van Lochem EG; Wiegers YM; van den Beemd R; Hählen K; van Dongen JJ; Hooijkaas H
Leukemia; 2000 Apr; 14(4):688-95. PubMed ID: 10764156
[TBL] [Abstract][Full Text] [Related]
15. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.
Li Y; Moriyama T; Yoshimura S; Zhao X; Li Z; Yang X; Paietta E; Litzow MR; Konopleva M; Yu J; Inaba H; Ribeiro RC; Pui CH; Yang JJ
Sci Adv; 2022 Dec; 8(50):eadd6403. PubMed ID: 36516256
[TBL] [Abstract][Full Text] [Related]
16. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
[TBL] [Abstract][Full Text] [Related]
18. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.
Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Nishida J; Kanda Y
Ann Hematol; 2016 Jan; 95(1):87-92. PubMed ID: 26391025
[TBL] [Abstract][Full Text] [Related]
20. Curcumin potentiates antitumor activity of L-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia.
Wang H; Geng QR; Wang L; Lu Y
Leuk Lymphoma; 2012 Jul; 53(7):1376-82. PubMed ID: 22185211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
